Chemotherapy and radiation for esophageal adenocarcinoma
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs given together with radiation therapy, followed by additional chemotherapy, for newly diagnosed adenocarcinoma (a type of cancer) in the esophagus or where the esophagus meets the stomach. The goal is to shrink the tumor and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed adenocarcinoma of the esophagus or gastroesophageal junction confirmed by biopsy
- Stage II-IVA disease (moderate to advanced, but not the most severe T4b type)
- No evidence of cancer spread to other parts of the body
- Able to receive chemotherapy drugs (carboplatin, paclitaxel, FLOT, or m-FOLFOX-6) and radiation therapy
- Good overall health and blood/kidney/liver function to tolerate treatment
- No prior chemotherapy, radiation therapy, or other cancer treatments for this diagnosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining chemotherapy (FLOT) with a special type of MRI-guided radiation before surgery for esophageal adenocarcinoma. It aims to improve treatment results for patients with a specific type and stage of the disease.
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
This study tests a new pre-surgery treatment plan that combines chemotherapy with focused, shorter-course radiation for esophagus or stomach-where-it-meets-the-esophagus (GEJ) adenocarcinoma. The goal is to shrink the tumor before surgery and improve treatment outcomes.
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
This trial is testing a new treatment approach for esophageal cancer that includes chemotherapy and immunotherapy before surgery. The goal is to see if this combination can help shrink the tumor and improve outcomes.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.